苁蓉益肾颗粒联合美金刚治疗帕金森痴呆的临床研究
|
摘要
目的观察苁蓉益肾颗粒联合盐酸美金刚片治疗帕金森痴呆的临床效果。方法选取2016年2月—2017年2月海南省安宁医院收治的帕金森痴呆患者90例,随机分为对照组和治疗组,每组各45例。对照组口服盐酸美金刚片,第1周剂量为5 mg/次,1次/d;第2周剂量为5 mg/次,2次/d;第3周剂量早上服用10 mg/次,晚上服用5 mg/次;从第4周开始维持剂量为早晚各服用10 mg/次,2次/d。治疗组在对照组治疗基础上口服苁蓉益肾颗粒,2 g/次,2次/d。两组均持续治疗3个月。观察两组的临床疗效,比较两组治疗前后简易智能精神状态检查表(MMSE)评分,日常生活能力量表(ADL)评分、统一帕金森病评分量表(UPDRS)评分、血清重组人帕金森病蛋白7(PARK7)、干扰素-γ(IFN-γ)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为68.89%、86.67%。两组比较差异具有统计学意义(P<0.05)。治疗后,两组定向力评分、语言能力评分、计算力和注意力评分、记忆力评分、ADL评分均显著高于治疗前,UPDRS评分显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组定向力评分、语言能力评分、计算力和注意力评分、记忆力评分、ADL评分显著高于对照组,UPDRS评分显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清PARK7、IFN-γ水平显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组PARK7、IFN-γ水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论苁蓉益肾颗粒联合盐酸美金刚片治疗帕金森痴具有较好的临床疗效,可有效提高患者生活质量和日常生活能力,改善认知功能,降低血清PARK7、IFN-γ水平,具有一定的临床推广应用价值。
Objective To investigate the efficacy of Congrong Yishen Granules combined with Memantine Hydrochloride Tablets in treatment of parkinson disease with dementia. Methods Patients(90 cases) with parkinson disease with dementia in Anning Hospital of Hainan February 2016 to February 2017 were randomly divided into control(45 cases) and treatment(45 cases) groups. Patients in the control group were po administered with Memantine Hydrochloride Tablets The was 5 mg/time in first week dosage, once daily. The dosage was 5 mg/time in second week, twice daily. In the third week, the dosage was 10 mg/time in the morning and 5 mg/time in the evening. Starting from the fourth week, the maintenance dosage was 10 mg/time, twice daily. Patients in the treatment group were po administered with Congrong Yishen Granules on the basis of the control group, 2 g/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of MMSE score, ADL score, UPDRS score, PARK7, and IFN-γ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 68.89% and 86.67%, and there were differences between two groups(P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in two groups were significantly increased, but UPDRS scores were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in the treatment group were higher than those in the control group, but UPDRS score was lower than that in the control group, and there were differences between two groups(P < 0.05). After treatment, PARK7 and IFN-γ were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, PARK7 and IFN-γ in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Congrong Yishen Granules combined with Memantine Hydrochloride Tablets has significant clinical effect in treatment of parkinson disease with dementia, and can effectively improve life quality, and also can improve cognitive function, and reduce serum PARK7 and IFN-γ, which has a certain clinical application value.
Objective To investigate the efficacy of Congrong Yishen Granules combined with Memantine Hydrochloride Tablets in treatment of parkinson disease with dementia. Methods Patients(90 cases) with parkinson disease with dementia in Anning Hospital of Hainan February 2016 to February 2017 were randomly divided into control(45 cases) and treatment(45 cases) groups. Patients in the control group were po administered with Memantine Hydrochloride Tablets The was 5 mg/time in first week dosage, once daily. The dosage was 5 mg/time in second week, twice daily. In the third week, the dosage was 10 mg/time in the morning and 5 mg/time in the evening. Starting from the fourth week, the maintenance dosage was 10 mg/time, twice daily. Patients in the treatment group were po administered with Congrong Yishen Granules on the basis of the control group, 2 g/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of MMSE score, ADL score, UPDRS score, PARK7, and IFN-γ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 68.89% and 86.67%, and there were differences between two groups(P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in two groups were significantly increased, but UPDRS scores were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in the treatment group were higher than those in the control group, but UPDRS score was lower than that in the control group, and there were differences between two groups(P < 0.05). After treatment, PARK7 and IFN-γ were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, PARK7 and IFN-γ in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Congrong Yishen Granules combined with Memantine Hydrochloride Tablets has significant clinical effect in treatment of parkinson disease with dementia, and can effectively improve life quality, and also can improve cognitive function, and reduce serum PARK7 and IFN-γ, which has a certain clinical application value.
引文
[1]潘宁丰,叶民.帕金森痴呆的临床诊断相关指标的研究进展[J].临床神经病学杂志,2014,27(6):473-476.
[2]范伟女,洪文轲,管琼峰.盐酸美金刚治疗帕金森痴呆患者的疗效观察[J].中华全科医学,2015,13(5):722-724.
[3]谢静红.帕金森病的中医药治疗近况[J].光明中医,2017,32(14):2137-2139.
[4]中华医学会神经病学分会帕金森病及运动障碍学组.帕金森病痴呆的诊断与治疗指南[J].中华神经科杂志,2011,44(9):635-637.
[5]郑筱萸.中医新药临床研究指导原则[M].北京:中国医药科技出版社,2002:1-99.
[6]Folstein M F,Folstein S E,Mchugh P R."Mini-mental state".A practical method for grading the cognitive state of patients for the clinician[J].J Psychiatric Res,1975,12(3):189-198.
[7]Caplan B.Lawton-Brody i ADL Scale[M].New York:Springer New York,2011:210-213.
[8]陈海波.统一帕金森病评定量表[J].中华老年医学杂志,1999,18(1):61-62.
[9]钟德芳.帕金森病痴呆的临床特征及诊治研究进展[J].中外医学研究,2016,14(7):163-164.
[10]高伟.盐酸美金刚对帕金森痴呆患者认知功能和日常生活能力的改善效果分析[J].河南医学研究,2015,24(12):113-114.
[11]倪小青,张家伟,张晓飞,等.盐酸美金刚治疗老年帕金森病痴呆患者的临床疗效[J].中国老年学,2013,33(20):4969-4970.
[12]吴晶晶,张临洪.苁蓉益智胶囊治疗帕金森性痴呆的临床研究[J].中药药理与临床,2015,31(6):158-160.
[13]顾超,沈婷,袁灿兴,等.苁蓉益肾颗粒联合盐酸多奈哌齐片治疗帕金森病痴呆的临床研究[J].中国药房,2017,28(17):2377-2380.
[14]Camargo C H F,Serpa R A,Matnei T,et al.The perception of apathy by caregivers of patients with dementia in Parkinson’s disease[J].Dement Neuropsychol,2016,10(4):339-343.
[15]时鹏,屈洪党,李强,等.帕金森病患者血清活化T细胞趋化因子和炎症因子水平及其临床意义[J].蚌埠医学院学报,2016,41(9):1132-1135.
[16]崔桂萍,刘萍.脑卒中患者血清PARK7水平变化及意义[J].山东医药,2013,53(24):12-14.
[17]王叶冉,刘雨辉,梁春荣,等.帕金森病患者血清炎症因子水平及其临床意义[J].重庆医学,2014,43(15):1848-1850.
[2]范伟女,洪文轲,管琼峰.盐酸美金刚治疗帕金森痴呆患者的疗效观察[J].中华全科医学,2015,13(5):722-724.
[3]谢静红.帕金森病的中医药治疗近况[J].光明中医,2017,32(14):2137-2139.
[4]中华医学会神经病学分会帕金森病及运动障碍学组.帕金森病痴呆的诊断与治疗指南[J].中华神经科杂志,2011,44(9):635-637.
[5]郑筱萸.中医新药临床研究指导原则[M].北京:中国医药科技出版社,2002:1-99.
[6]Folstein M F,Folstein S E,Mchugh P R."Mini-mental state".A practical method for grading the cognitive state of patients for the clinician[J].J Psychiatric Res,1975,12(3):189-198.
[7]Caplan B.Lawton-Brody i ADL Scale[M].New York:Springer New York,2011:210-213.
[8]陈海波.统一帕金森病评定量表[J].中华老年医学杂志,1999,18(1):61-62.
[9]钟德芳.帕金森病痴呆的临床特征及诊治研究进展[J].中外医学研究,2016,14(7):163-164.
[10]高伟.盐酸美金刚对帕金森痴呆患者认知功能和日常生活能力的改善效果分析[J].河南医学研究,2015,24(12):113-114.
[11]倪小青,张家伟,张晓飞,等.盐酸美金刚治疗老年帕金森病痴呆患者的临床疗效[J].中国老年学,2013,33(20):4969-4970.
[12]吴晶晶,张临洪.苁蓉益智胶囊治疗帕金森性痴呆的临床研究[J].中药药理与临床,2015,31(6):158-160.
[13]顾超,沈婷,袁灿兴,等.苁蓉益肾颗粒联合盐酸多奈哌齐片治疗帕金森病痴呆的临床研究[J].中国药房,2017,28(17):2377-2380.
[14]Camargo C H F,Serpa R A,Matnei T,et al.The perception of apathy by caregivers of patients with dementia in Parkinson’s disease[J].Dement Neuropsychol,2016,10(4):339-343.
[15]时鹏,屈洪党,李强,等.帕金森病患者血清活化T细胞趋化因子和炎症因子水平及其临床意义[J].蚌埠医学院学报,2016,41(9):1132-1135.
[16]崔桂萍,刘萍.脑卒中患者血清PARK7水平变化及意义[J].山东医药,2013,53(24):12-14.
[17]王叶冉,刘雨辉,梁春荣,等.帕金森病患者血清炎症因子水平及其临床意义[J].重庆医学,2014,43(15):1848-1850.